Significant tumor regression induced by microencapsulation of recombinant tumor cells secreting fusion protein

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 3, 2005, Pages 260-266

  Shi, Meiqing ^a   Hao, Siguo ^a   Quereshi, Mabood ^a   Guo, Xulin ^a   Zheng, Changyu ^b   Xiang, Jim ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Antitumor; Microencapsulation; Recombinant cells; RM4 TNF

Indexed keywords

HYBRID PROTEIN; TUMOR ANTIGEN; TUMOR ANTIGEN TAG72; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CANCER GENETICS; CELL SECRETION; CONTROLLED STUDY; CYTOTOXICITY; GENE THERAPY; GENETIC ENGINEERING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MICROENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR CELL LINE; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG COMPOUNDING; MICE; NEOPLASMS; RATS; RECOMBINANT FUSION PROTEINS; TISSUE THERAPY; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 22344455755     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.260     Document Type: Article

References (30)

1. Cars well EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666.
2. Philip R, Epstein LB. Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon, and interleukin-1. Nature 1986;323:86.
3. Talmadge JE, Phillips H, Schneider M, et al. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res 1988;48:544.
4. Shalaby MR, Aggarwal BB, Rinderknecht E, et al. Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol 1985;135:2069.
5. Ranges GE, Figari IS, Espevik T, et al. Inhibition of cytotoxic T-cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med 1987;166:991.
6. Robinet E, Branellec D, Termijtelen AM, et al. Evidence for tumor necrosis factor-alpha involvement in the optimal induction of class I allospecific cytotoxic T-cells. J Immunol 1990;144:4555.
7. Asher A, Mule JJ, Reichert CM, et al. Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963.
8. Creasey AA, Reynolds MT, Laird W. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res 1986;46: 5687.
9. Sherman ML, Spriggs DR, Arthur KA, et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: Phase I toxicity and effects on lipid metabolism. J Clin Oncol 1988;6:344.
10. Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988;80:1039.
11. Creaven PJ, Plager JE, Dupere S, et al. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1987;20:137.
12. de Harven E, Fradet Y, Connolly JG, et al. Antibody drug carrier for immunotherapy of superficial bladder cancer: Ultrastructural studies. Cancer Res 1992;52: 3131.
13. FitzGerald DJ, Willingham MC, Cardarelli CO, et al. A monoclonal antibody-pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci USA 1987;84:4288.
14. Thor A, Ohuchi N, Szpak CA, et al. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986;46:3118.
15. Xiang J, Moyana T, Kalra J, et al. Construction and characterization of a high-affinity chimeric anticolorectal carcinoma antibody ccM4. Mol Biother 1992;4:174.
16. 2 and tumor necrosis factor. J Biotechnol 1997;53:3.
17. Chang PL, Van Raamsdonk JM, Hortelano G, et al. The in vivo delivery of heterologous proteins by microencapsulated recombinant cells. Trends Biotechnol 1999;17:78.
18. Cirone P, Bourgeois JM, Austin RC, Chang PL. A novel approach to tumor suppression with microencapsulated recombinant cells. Hum Gene Ther 2002;13:1157.
19. Joki T, Machluf M, Atala A, et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 2001;19:35.
20. Schwenter F, Schneider BL, Pralong WF, et al. Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions. Hum Gene Ther 2004;15:669.
21. Van Raamsdonk JM, Ross CJ, Potter MA, et al. Treatment of hemophilia B in mice with nonautologous somatic gene therapeutics. J Lab Clin Med 2002;139:35.
22. Xiang J, Qi Y, Cook D, et al. Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells. Hum Antibodies Hybridomas 1996;7:2.
23. Liu Y, Huang H, Chen Z, et al. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T- and natural killer cell cytotoxicities and antitumor immunity. J Gene Med 2003;5:668.
24. Koshita Y, Lu Y, Fujii S. Efficacy of TNF-alpha gene-transduced tumor cells in treatment of established in vivo tumor. Int J Cancer 1995;63:130.
25. Xiang J, Qi Y, Chen Y. Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF. Cancer Gene Ther 1997;4:353.
26. Wright P, Braun R, Babiuk L, et al. Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm 1999;14:49.
27. Sarraf C. Tumor necrosis factor and cell death in tumors. Int J Oncol 1994;5:1333.
28. Tracey KJ, Cerami A. Tumor necrosis factor: A pleiotropic cytokine and therapeutic target. Annu Rev Med 1994;45:491.
29. Ruegg C, Yilmaz A, Bieler G, et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF- and IFN-gamma. Nat Med 1998;4:408.
30. Denekamp J. Review article: Angiogenesis, neovascular proliferation, and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993;66:181.